| scholarly article | Q13442814 |
| P2093 | author name string | James McGinty | |
| Blandine Laferrère | |||
| Julio Teixeira | |||
| Antonia Colarusso | |||
| Baani Bawa | |||
| Ninan Koshy | |||
| Hongchan Lee | |||
| Joseph R Egger | |||
| Hao Tran | |||
| Blanca Olivan | |||
| Betty Kovack | |||
| Kimberly Yapp | |||
| P2860 | cites work | Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases | Q28294992 |
| The Physiology of Glucagon-like Peptide 1 | Q28373115 | ||
| Bariatric surgery: a systematic review and meta-analysis | Q30769299 | ||
| Postprandial glucose regulation: new data and new implications | Q31033684 | ||
| Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. | Q33225025 | ||
| Trends in mortality in bariatric surgery: a systematic review and meta-analysis | Q33303296 | ||
| Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. | Q34327135 | ||
| Highly variable gastric emptying in patients with insulin dependent diabetes mellitus | Q34408548 | ||
| Attenuated GLP-1 secretion in obesity: cause or consequence? | Q34409856 | ||
| Absorption of glucose, sodium, and water by the human jejunum studied by intestinal perfusion with a proximal occluding balloon and at variable flow rates | Q34473266 | ||
| Biological actions and therapeutic potential of the glucagon-like peptides | Q34520645 | ||
| Extrapancreatic effects of GIP and GLP-1. | Q36012504 | ||
| Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors | Q36056970 | ||
| Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding | Q36259482 | ||
| Bariatric surgery: effects on glucose homeostasis | Q36508543 | ||
| Incretins and the development of type 2 diabetes | Q36560963 | ||
| Incretin hormone mimetics and analogues in diabetes therapeutics | Q37022361 | ||
| Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes | Q37345249 | ||
| Gastric emptying and release of incretin hormones after glucose ingestion in humans | Q39759027 | ||
| Gut Hormones | Q40098234 | ||
| Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects* | Q40329405 | ||
| Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects | Q41189471 | ||
| The prevention and treatment of obesity. Application to type 2 diabetes | Q41629185 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects | Q42476857 | ||
| Gastrointestinal adaptation to diets of differing fat composition in human volunteers | Q43048461 | ||
| Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients | Q43705651 | ||
| Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. | Q44764978 | ||
| Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty | Q44969260 | ||
| Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects | Q46484204 | ||
| Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. | Q46783348 | ||
| Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes | Q46907739 | ||
| Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal | Q46982079 | ||
| Long-term effects of modest weight loss in type II diabetic patients | Q47191274 | ||
| Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects | Q47226497 | ||
| Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study | Q47256275 | ||
| Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters | Q47356520 | ||
| Year-long weight loss treatment for obese patients with type II diabetes: does including an intermittent very-low-calorie diet improve outcome? | Q47368378 | ||
| Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats | Q47405665 | ||
| Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion | Q47773320 | ||
| Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. | Q47790721 | ||
| Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. | Q48457433 | ||
| Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. | Q50888248 | ||
| GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. | Q51481151 | ||
| Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. | Q51562589 | ||
| Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. | Q51634818 | ||
| Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. | Q53180211 | ||
| Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. | Q53532607 | ||
| GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans | Q58448859 | ||
| Gastric inhibitory polypeptide (GIP) release and incretin effect after oral glucose in obesity and after jejunoileal bypass | Q67239144 | ||
| Reduced incretin effect in type 2 (non-insulin-dependent) diabetes | Q68865252 | ||
| Gastric emptying after gastric bypass | Q69548064 | ||
| Morphological and functional alterations to a sub-group of regulatory peptides in human pancreas and intestine after jejuno-ileal bypass | Q72213559 | ||
| The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction | Q74287135 | ||
| Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses | Q93538767 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 2479-2485 | |
| P577 | publication date | 2008-04-22 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes | |
| P478 | volume | 93 |
| Q89559237 | "Dysfunctions" induced by Roux-en-Y gastric bypass surgery are concomitant with metabolic improvement independent of weight loss |
| Q22241093 | "Metabolic" Surgery for Treatment of Type 2 Diabetes Mellitus |
| Q49497762 | A Murine Model of Vertical Sleeve Gastrectomy |
| Q38135439 | A brief history of the surgery for obesity to the present, with an overview of nutritional implications |
| Q37727228 | A case report: Liraglutide as a novel treatment option in late dumping syndrome. |
| Q36454431 | A closer look at diabetes remission after gastric bypass surgery: a case study |
| Q35232361 | A meta-analysis of short-term outcomes of patients with type 2 diabetes mellitus and BMI ≤ 35 kg/m2 undergoing Roux-en-Y gastric bypass |
| Q51378838 | A model for predicting the resolution of type 2 diabetes in severely obese subjects following Roux-en Y gastric bypass surgery. |
| Q35573512 | Activation of natriuretic peptides and the sympathetic nervous system following Roux-en-Y gastric bypass is associated with gonadal adipose tissues browning |
| Q36203380 | Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women |
| Q37427308 | Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? |
| Q37889178 | Advances in the etiology and management of hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass |
| Q51314561 | Age and gender may influence the results of Roux-en-Y gastric bypass? Metabolic syndrome parameters. |
| Q36134542 | All bariatric surgeries are not created equal: insights from mechanistic comparisons |
| Q36426666 | Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery |
| Q46116217 | Alterations in proinsulin and insulin dynamics, HDL Cholesterol and ALT after gastric bypass surgery. A 42-months follow-up study |
| Q33682506 | Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia |
| Q47210652 | An Optimized IES Method and Its Inhibitory Effects and Mechanisms on Food Intake and Body Weight in Diet-Induced Obese Rats: IES for Obesity |
| Q37662974 | Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice |
| Q64965992 | Bariatric Surgery Modulates Urinary Levels of MicroRNAs Involved in the Regulation of Renal Function. |
| Q33711409 | Bariatric Surgery and Liver Transplantation |
| Q37930951 | Bariatric surgeries: beyond restriction and malabsorption |
| Q41809362 | Bariatric surgery and T2DM improvement mechanisms: a mathematical model. |
| Q34453612 | Bariatric surgery and diabetes: who should be offered the option of remission? |
| Q37812853 | Bariatric surgery and its impact on sleep architecture, sleep-disordered breathing, and metabolism |
| Q33838154 | Bariatric surgery and obesity: influence on the incretins |
| Q36163431 | Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass? |
| Q39871850 | Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus |
| Q51553915 | Bariatric surgery for diabetes: the International Diabetes Federation takes a position. |
| Q34280152 | Bariatric surgery for type 2 diabetes |
| Q35008794 | Bariatric surgery for type 2 diabetes: weighing the impact for obese patients |
| Q35971290 | Bariatric surgery in hypothalamic obesity |
| Q37691684 | Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes |
| Q33602173 | Bariatric surgery reduces oxidative stress by blunting 24-h acute glucose fluctuations in type 2 diabetic obese patients |
| Q35069674 | Bariatric surgery: an IDF statement for obese Type 2 diabetes |
| Q42795731 | Bariatric surgery: an attractive therapeutic modality for type 2 diabetes mellitus |
| Q37979723 | Bariatric surgery: effects on the metabolic complications of obesity. |
| Q34497673 | Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention |
| Q53055923 | Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. |
| Q37230776 | Biological mechanisms that promote weight regain following weight loss in obese humans |
| Q35217475 | Biology's response to dieting: the impetus for weight regain |
| Q37620091 | Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. |
| Q36885523 | Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss |
| Q35769505 | Calorie Restriction and Matched Weight Loss From Exercise: Independent and Additive Effects on Glucoregulation and the Incretin System in Overweight Women and Men |
| Q57148414 | Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects |
| Q50259673 | Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes |
| Q89159602 | Can Bariatric Surgery be Considered Standard Therapy to Treat Type 2 Diabetes? |
| Q51744999 | Can Helicobacter pylori Eradication Treatment Modify the Metabolic Response to Bariatric Surgery? |
| Q39076089 | Changes in Fasting and Prandial Gut and Adiposity Hormones Following Vertical Sleeve Gastrectomy or Roux-en-Y-Gastric Bypass: an 18-Month Prospective Study |
| Q85888200 | Changes in GIP gene expression following bariatric surgery |
| Q44621765 | Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects |
| Q34824005 | Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review |
| Q34824270 | Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery |
| Q39001088 | Changes in glycemia, insulin and gut hormone responses to a slowly ingested solid low-carbohydrate mixed meal after laparoscopic gastric bypass or band surgery |
| Q51294308 | Changes in insulin sensitivity and secretion after sleeve gastrectomy. |
| Q30391329 | Changes in neurohormonal gut peptides following bariatric surgery |
| Q46116312 | Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion |
| Q37979850 | Clinical considerations for the management of residual diabetes following bariatric surgery |
| Q55668670 | Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Soc |
| Q34075016 | Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Soc |
| Q26991653 | Clues from bariatric surgery: reversing insulin resistance to heal the heart |
| Q95382998 | Collaboration between basic science researchers and bariatric surgeons is a win/win proposition: view from the chair |
| Q53671354 | Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. |
| Q35669476 | Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males. |
| Q36479829 | Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms |
| Q36896558 | Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss |
| Q35033491 | Consequences of obesity and weight loss: a devil's advocate position |
| Q37670181 | Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass |
| Q38211505 | Control of type 2 diabetes after 1 year of laparoscopic adjustable gastric banding in the helping evaluate reduction in obesity (HERO) study |
| Q37939367 | Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. |
| Q38812184 | Diabetes after Bariatric Surgery |
| Q37564116 | Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis |
| Q37930945 | Diabetes remission after bariatric surgery: is it just the incretins? |
| Q38129779 | Diabetes remission following metabolic surgery: is GLP-1 the culprit? |
| Q30394286 | Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. |
| Q30277979 | Differences in Weight Loss and Gut Hormones: Rouen-Y Gastric Bypass and Sleeve Gastrectomy Surgery |
| Q36851000 | Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss |
| Q33789529 | Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? |
| Q27026687 | Do we really know why diabetes remits after gastric bypass surgery? |
| Q37110503 | Does caloric restriction alone explain the effects of Roux-en-Y gastric bypass on glucose metabolism? Not by a long limb |
| Q37697736 | Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass in morbidly obese patients? |
| Q34748035 | Dual mechanism for type-2 diabetes resolution after Roux-en-Y gastric bypass |
| Q41641006 | Duodenal Electric Stimulation: Results of a First-in-Man Study. |
| Q38686646 | Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia |
| Q38191195 | Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients |
| Q45986635 | Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. |
| Q37339611 | EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL. |
| Q51034517 | Early 24-hour blood pressure response to Roux-en-Y gastric bypass in obese patients. |
| Q46854679 | Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients |
| Q51329348 | Early improvement of postprandial lipemia after bariatric surgery in obese type 2 diabetic patients. |
| Q43241597 | Early postoperative insulin-resistance changes after sleeve gastrectomy |
| Q47416302 | Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats |
| Q33743998 | Effect of gastric bypass surgery on the incretins |
| Q36339659 | Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test |
| Q47180661 | Effect of meal size and texture on gastric pouch emptying and glucagon-like peptide 1 after gastric bypass surgery |
| Q48124060 | Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. |
| Q33752066 | Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels |
| Q27011627 | Effects of GLP-1 on appetite and weight |
| Q38270358 | Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency |
| Q36292243 | Effects of bariatric surgery on glucose homeostasis and type 2 diabetes |
| Q26995145 | Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery |
| Q37340237 | Effects of meal composition on postprandial incretin, glucose and insulin responses after surgical and medical weight loss |
| Q42955206 | Electrical stimulation of the isolated rat intestine in the presence of nutrient stimulus enhances glucagon-like peptide-1 release |
| Q39390970 | Endocrine Function after Bariatric Surgery |
| Q37226877 | Endocrine and metabolic response to gastric bypass |
| Q64286442 | Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones |
| Q37442596 | Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery |
| Q47094048 | European Guidelines for Obesity Management in Adults. |
| Q46159970 | Evaluation of the influence of whole and defatted flaxseed on satiety, glucose, and leptin levels of women in the late postoperative stage of bariatric surgery |
| Q37110621 | Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. |
| Q41952935 | Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm |
| Q64990953 | From Normal to Obesity and Back: The Associations between Mitochondrial DNA Copy Number, Gender, and Body Mass Index. |
| Q38160207 | From bariatric to metabolic surgery: definition of a new discipline and implications for clinical practice |
| Q38095825 | From gut changes to type 2 diabetes remission after gastric bypass surgeries |
| Q92784035 | Fructose Consumption Contributes to Hyperinsulinemia in Adolescents With Obesity Through a GLP-1-Mediated Mechanism |
| Q37809995 | GIP and bariatric surgery |
| Q36942165 | GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery |
| Q35360690 | GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification |
| Q38307449 | GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery? |
| Q47745704 | GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice. |
| Q39253990 | Gastric Bypass and Influence on Improvement of NAFLD. |
| Q37691668 | Gastric bypass and glucose metabolism |
| Q34442926 | Gastric bypass promotes more lipid mobilization than a similar weight loss induced by low-calorie diet |
| Q35179981 | Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans |
| Q89599740 | Gastric bypass surgery in a rat model alters the community structure and functional composition of the intestinal microbiota independently of weight loss |
| Q40846490 | Gastric bypass surgery in non-obese patients with type 2 diabetes mellitus: a 1-year follow-up of 58 cases in Chinese. |
| Q35827899 | Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction |
| Q36850966 | Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes |
| Q39047697 | Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB. |
| Q38345800 | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway |
| Q47249342 | Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect |
| Q42954375 | Glucose-Stimulated Insulin Secretion in Gastric Bypass Patients with Hypoglycemic Syndrome: No Evidence for Inappropriate Pancreatic β-cell Function |
| Q37911549 | Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders |
| Q42936637 | Going with the flow: adaptation of β-cell function to glucose fluxes after bariatric surgery |
| Q37990142 | Gut feelings about diabetes |
| Q64261023 | Gut microbiota specific signatures are related to the successful rate of bariatric surgery |
| Q89888547 | High-Resolution Three-Dimensional Photonic Scan-Derived Equations Improve Body Surface Area Prediction in Diverse Populations |
| Q33569986 | Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia |
| Q38845417 | How to Choose the Best Metabolic Procedure? |
| Q34775887 | Hypertrophy dependent doubling of L-cells in Roux-en-Y gastric bypass operated rats. |
| Q57181863 | Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders |
| Q34178868 | Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. |
| Q48231744 | Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass |
| Q37105254 | Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes |
| Q38335305 | Improvement in insulin sensitivity and β-cell function following ileal interposition with sleeve gastrectomy in type 2 diabetic patients: potential mechanisms. |
| Q37475666 | Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost |
| Q34305172 | Improvement in ß-cell function in patients with normal and hyperglycemia following Roux-en-Y gastric bypass surgery. |
| Q38793432 | Influence of dietary protein and its amino acid composition on postoperative outcomes after gastric bypass surgery: a systematic review |
| Q38021556 | Insulin sensitivity and secretion modifications after bariatric surgery |
| Q46013901 | Interdisciplinary European Guidelines on metabolic and bariatric surgery. |
| Q53102466 | Interdisciplinary European guidelines on metabolic and bariatric surgery. |
| Q36454360 | Isolated duodenal exclusion increases energy expenditure and improves glucose homeostasis in diet-induced obese rats |
| Q39754426 | Key details of the duodenal-jejunal bypass in type 2 diabetes mellitus rats |
| Q51330445 | Laparoscopic greater curvature plication in morbidly obese women with type 2 diabetes: effects on glucose homeostasis, postprandial triglyceridemia and selected gut hormones. |
| Q38794942 | Late endocrine effects of childhood cancer |
| Q57591304 | Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet |
| Q37660926 | Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission |
| Q41970987 | Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients |
| Q36691538 | Longitudinal assessment of food intake, fecal energy loss, and energy expenditure after Roux-en-Y gastric bypass surgery in high-fat-fed obese rats |
| Q35620202 | Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery |
| Q37463193 | Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. |
| Q37422041 | Meal patterns, satiety, and food choice in a rat model of Roux-en-Y gastric bypass surgery |
| Q33772412 | Meal-induced hormone responses in a rat model of Roux-en-Y gastric bypass surgery |
| Q26780440 | Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review |
| Q37311381 | Mechanism for improved insulin sensitivity after gastric bypass surgery |
| Q41945986 | Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. |
| Q90680833 | Mechanisms Underlying Type 2 Diabetes Remission After Metabolic Surgery |
| Q37053538 | Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetes |
| Q47610898 | Mechanisms by which a Very-Low-Calorie Diet Reverses Hyperglycemia in a Rat Model of Type 2 Diabetes |
| Q53784109 | Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. |
| Q26865399 | Mechanisms of Weight Regain following Weight Loss |
| Q57154153 | Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery |
| Q37691664 | Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery |
| Q37357840 | Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat |
| Q38005896 | Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass |
| Q37212797 | Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe |
| Q35529693 | Mechanisms responsible for excess weight loss after bariatric surgery |
| Q38096980 | Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective |
| Q57192793 | Metabolic comparison of one-anastomosis gastric bypass, single-anastomosis duodenal-switch, Roux-en-Y gastric bypass, and vertical sleeve gastrectomy in rat |
| Q37022586 | Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment |
| Q35716332 | Metabolic surgery and intestinal gene expression: Digestive tract and diabetes evolution considerations. |
| Q37718082 | Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies |
| Q37898157 | Metabolic surgery for type 2 diabetes |
| Q37922651 | Metabolic surgery-principles and current concepts |
| Q27010589 | Metabolic surgery: action via hormonal milieu changes, changes in bile acids or gut microbiota? A summary of the literature |
| Q88532507 | Metabolic surgery: gastric bypass for the treatment of type 2 diabetes mellitus |
| Q47179053 | Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health |
| Q34392834 | Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. |
| Q27026927 | Mineral malnutrition following bariatric surgery |
| Q36747962 | Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. |
| Q37788953 | Morbid obesity in pediatric diabetes mellitus: surgical options and outcomes |
| Q57069665 | Non-insulin determinant pathways maintain glucose homeostasis upon metabolic surgery |
| Q83782939 | Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes |
| Q30351930 | Obesity and the need for bariatric surgery in Pakistan. |
| Q35054892 | Obesity surgery and gut-brain communication |
| Q37511828 | Obesity, gut hormones, and bariatric surgery. |
| Q38126800 | Obesity-related cardiorenal disease: the benefits of bariatric surgery |
| Q38514840 | Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones |
| Q38734496 | Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery |
| Q36955246 | Peripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in mice |
| Q92283963 | Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol |
| Q38965089 | Physiological and molecular responses to bariatric surgery: markers or mechanisms underlying T2DM resolution? |
| Q45951720 | Plasma glucose and insulin regulation is abnormal following gastric bypass surgery with or without neuroglycopenia. |
| Q92525679 | Portal milieu and the interplay of multiple antidiabetic effects after gastric bypass surgery |
| Q41832470 | Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report |
| Q38053261 | Potential mechanisms by which bariatric surgery improves systemic metabolism |
| Q38232790 | Predicting remission of diabetes after RYGB surgery following intensive management to optimize preoperative glucose control |
| Q58447498 | Preoperative β-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery |
| Q35973869 | Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass |
| Q89816434 | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague-Dawley Rat Model |
| Q33165603 | Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy |
| Q90629095 | Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study |
| Q93069025 | Proinsulin associates with poor β-cell function, glucose-dependent insulinotropic peptide, and insulin resistance in persistent type 2 diabetes after Roux-en-Y gastric bypass in humans |
| Q37261091 | Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass |
| Q36496603 | Protocol for a randomised clinical study comparing the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on reactive hypoglycaemia in morbidly obese subjects. |
| Q38443867 | Pulmonary function and blood gases after gastric bypass and lifestyle intervention: a comparative study. |
| Q92947512 | Rapid changes in neuroendocrine regulation may contribute to reversal of type 2 diabetes after gastric bypass surgery |
| Q37106477 | Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery? |
| Q38849378 | Recent advances in the modification of taste and food preferences following bariatric surgery. |
| Q24563430 | Regulation of glucose homeostasis by GLP-1 |
| Q27022123 | Relationship between gut hormones and glucose homeostasis after bariatric surgery |
| Q93078585 | Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction? |
| Q34113935 | Resolution of type 2 diabetes following bariatric surgery: implications for adults and adolescents |
| Q43281624 | Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? |
| Q34191173 | Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. |
| Q34032014 | Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes |
| Q35963032 | Role of Gut-Related Peptides and Other Hormones in the Amelioration of Type 2 Diabetes after Roux-en-Y Gastric Bypass Surgery |
| Q38129778 | Role of metabolic surgery in less obese or non-obese subjects with type 2 diabetes: influence over cardiovascular events |
| Q37639656 | Role of the Gut on Glucose Homeostasis: Lesson Learned from Metabolic Surgery |
| Q34979966 | Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery |
| Q51245449 | Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission. |
| Q64230299 | Roux-en-Y Gastric Bypass Is Associated With Hyperinsulinemia But Not Increased Maximal -Cell Function |
| Q37337696 | Roux-en-Y gastric bypass alters small intestine glutamine transport in the obese Zucker rat. |
| Q37862878 | Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. |
| Q33844168 | Roux-en-Y gastric bypass promotes expression of PDX-1 and regeneration of beta-cells in Goto-Kakizaki rats |
| Q90730908 | Short-term effects of Vertical sleeve gastrectomy and Roux-en-Y gastric bypass on glucose homeostasis |
| Q64066317 | Sleeve gastrectomy rapidly enhances islet function independently of body weight |
| Q33879265 | Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding |
| Q37897480 | Surgical approaches to the treatment of obesity |
| Q30405974 | Surgical treatment of type 2 diabetes: the surgeon perspective. |
| Q51454044 | Symptoms suggestive of dumping syndrome after provocation in patients after laparoscopic sleeve gastrectomy. |
| Q92431618 | THE INFLUENCE OF TOTAL OR SUB-TOTAL GASTRECTOMY ON GLUCOSE CONTROL IN DIABETIC AND NON-DIABETIC PATIENTS |
| Q37339623 | THE ROLE OF METABOLIC SURGERY FOR PATIENTS WITH OBESITY GRADE I AND TYPE 2 DIABETES NOT CONTROLLED CLINICALLY. |
| Q38894976 | THE ROLE OF METABOLIC SURGERY FOR PATIENTS WITH OBESITY GRADE I ANDCLINICALLY UNCONTROLLED TYPE 2 DIABETES. |
| Q55363824 | Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass. |
| Q92046689 | Temporal plasticity of insulin and incretin secretion and insulin sensitivity following sleeve gastrectomy contribute to sustained improvements in glucose control |
| Q51277741 | The Effects of One-Anastomosis Gastric Bypass on Glucose Metabolism in Goto-Kakizaki Rats. |
| Q64976609 | The EndoBarrier: Duodenal-Jejunal Bypass Liner for Diabetes and Weight Loss. |
| Q90533544 | The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity |
| Q50080451 | The Role of GLP-1 in the Metabolic Success of Bariatric Surgery |
| Q43294363 | The correlation between intestinal gonadotropin-releasing hormone (GnRH) and proglucagon in hyperlipidemic rats and Goto-Kakizaki (GK) rats |
| Q51359833 | The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass. |
| Q26783535 | The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones |
| Q37150286 | The effect of duodenojejunal bypass for type 2 diabetes mellitus patients below body mass index 25 kg/m(2): one year follow-up |
| Q38045820 | The effect of gastrointestinal surgery on insulin resistance and insulin secretion |
| Q38248570 | The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity |
| Q37897673 | The effects of weight loss strategies on gastric emptying and appetite control |
| Q37889275 | The emerging role of the intestine in metabolic diseases |
| Q41038731 | The endogenous preproglucagon system is not essential for gut growth homeostasis in mice |
| Q33696549 | The environment within: how gut microbiota may influence metabolism and body composition |
| Q37216719 | The glucose-dependent insulinotropic polypeptide and glucose-stimulated insulin response to exercise training and diet in obesity |
| Q37895979 | The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions. |
| Q84717616 | The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study |
| Q33932609 | The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery |
| Q38038435 | The importance of the gut microbiota after bariatric surgery |
| Q38733474 | The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions |
| Q30388925 | The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity |
| Q47176353 | The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis |
| Q38601589 | The role of obestatin in roux-en-Y gastric bypass-induced remission of type 2 diabetes mellitus |
| Q33761529 | The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgery |
| Q44585460 | The surgical treatment of type II diabetes mellitus: changes in HOMA Insulin resistance in the first year following laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB). |
| Q47159019 | Three-year result of efficacy for type 2 diabetes mellitus control between laparoscopic duodenojejunal bypass compared with laparoscopic Roux-en-Y gastric bypass |
| Q48092622 | Time to Glycemic Control - an Observational Study of 3 Different Operations. |
| Q51344856 | Tissue specificity in fasting glucose utilization in slightly obese diabetic patients submitted to bariatric surgery. |
| Q34512740 | Tissue-specific effects of bariatric surgery including mitochondrial function |
| Q37606019 | Treating diabetes and prediabetes by focusing on obesity management. |
| Q37609829 | Treating type 2 diabetes: incretin mimetics and enhancers |
| Q34734936 | Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models |
| Q46125804 | Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options |
| Q48014876 | Treatments for obesity: view from the Chair |
| Q48382824 | Two-year outcome of laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity: results from a Swedish Nationwide Study (AMOS). |
| Q37025587 | Type 2 Diabetes Remission Rates After Laparoscopic Gastric Bypass and Gastric Banding: Results of the Longitudinal Assessment of Bariatric Surgery Study |
| Q42753016 | Type 2 diabetes mellitus control and atherosclerosis prevention in a non-obese rat model using duodenal-jejunal bypass |
| Q37837496 | Type 2 diabetes mellitus--current therapies and the emergence of surgical options |
| Q102144608 | Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery |
| Q37110587 | Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients |
| Q34503739 | Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action |
| Q35132986 | Weight Loss as a Cure for Type 2 Diabetes? Fact or Fantasy |
| Q47355415 | Weight Regain After Gastric Bypass: Influence of Gut Hormones |
| Q34022466 | Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery |
| Q38636904 | Weight regain in patients with symptoms of post-bariatric surgery hypoglycemia |
| Q57108626 | Weight-Independent Mechanisms of Glucose Control After Roux-en-Y Gastric Bypass |
| Q38271009 | Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats |
| Q85778312 | [Surgery as pluripotent instrument for metabolic disease. What are the mechanisms?] |
| Q54443381 | [Type II diabetes. Permanent remission by surgery of the foregut]. |
| Q33816658 | β-cell function after weight-loss induced by bariatric surgery |
Search more.